ArticleNutrients2026
Proof of Principle: Short-Term Sulforaphane Precursor Intake Alters Selected Circulating Oxidative Stress and Muscle Damage Biomarkers Following Maximal Exercise: A Double-Blind Crossover Trial.
Article in Nutrients, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundEndurance exercise is known to induce the excessive production of reactive oxygen metabolites due to enhanced metabolic activity and inflammation, leading to oxidative stress and related injuries. Sulforaphane (SFN), an isothiocyanate, is broadly acknowledged for its potential antioxidant and anti-inflammatory properties, along with other protective functions.
objectiveThe purpose of this study was to investigate the effects of short-term SFN precursor supplementation on maximal exercise-induced muscle damage, oxidative stress and endurance capacity in healthy adults.
methodsIn a double-blind placebo-controlled crossover design, 14 healthy participants (7 males, 7 females; age, 25.07 ± 1.04 years; weight, 65.28 ± 4.13 kg; height, 170.07 ± 3.46 cm; BMI, 22.48 ± 0.91) received SFN glucosinolate capsules (200 µmol/day) or placebo for 2 weeks during the first trial. Following a three-week washout period, the participants crossed over to the alternate treatment. Maximal exercise tests were performed following each supplementation (SFN or placebo) period. Blood samples were collected at baseline (before treatment), pre-exercise, post-exercise and 2 h after each exercise session.
resultsSFN supplementation did not alter endurance capacity or blood cell counts; however, it significantly attenuated serum creatine kinase (CK) activity (
conclusionSFN intake may be a beneficial, non-invasive strategy to modulate acute biochemical responses to exercise via the antioxidant defense system in physically active individuals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.